The agreement lets Biotheranostics offer its CancerType ID and Breast Cancer Index genomic tests to customers through Syapse's software.
The two health systems have also joined the OPeN consortium and plan to share cancer patient data in support of the Cancer Moonshot Initiative.
Within the consortium community healthcare systems can contribute and access each other's data on cancer patients' molecular profiles and treatment outcomes.
The consortium aims to share aggregated data between its members, enabling more cancer patients to benefit from high volume-based analytics.
The company is seeking partnerships that will enable it to offer its software to more users as part of larger, more integrated systems.
Syapse is using the Series C funding to hire new staff and extend its Syapse Precision Medicine platform to support disease areas beyond cancer.
Members of Caris' Centers of Excellence for Precision Medicine Network will use the Syapse Precision Medicine Platform to merge data sets.
The companies are combining their respective software platforms to provide an end-to-end genomic testing solution for hospital labs.
The initiative aims to integrate clinical, genomic, environmental, and other data from patients to help determine disease mechanisms and develop precise therapies.
The partners plan to launch a service that will provide access to genomic testing, best practices guidelines, and decision support.
In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.
The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.
A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.
Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.